Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Roche, Oryzon Announce Epigenetics Collaboration

Published: Monday, April 07, 2014
Last Updated: Monday, April 07, 2014
Bookmark and Share
Collaboration spans research, development and commercialization of LSD1 inhibitors for oncology, haematology and non-malignant conditions.

Roche  and Oryzon Genomics SA announce they have entered into a worldwide collaboration to research, develop and commercialize inhibitors of Lysine Specific Demethylase-1 (LSD1; KDM1A), an epigenetic modulator that regulates gene expression. 

The lead molecule, ORY-1001, was granted orphan drug status by EMA in August 2013 and is currently in phase I/IIA for acute myeloid leukaemia (AML). Roche will have sole responsibility for developing and commercializing ORY-1001 and/or its backup compounds. The agreement includes the licensing of two patent families that Oryzon has created in its pioneering research in LSD1, and includes options for other Oryzon programs to be incorporated in future. The agreement also includes an initial two-year collaborative research program between Oryzon and Roche’s New York-based Translational Clinical Research Center (TCRC), Roche’s hub for research and early development activities in North America, to better understand the potential of LSD1 inhibitors in oncology and haematology. 

John Reed, Roche’s Head of Pharma Research and Early Development, commented, “Oryzon is working at the leading edge of LSD1 inhibition, a technology with great potential to bring genuine patient benefit. Our TCRC in New York has been launched with a mandate to identify partnerships that drive innovation, providing an industry-leading conduit between sources of breakthrough science and the broader Roche organization. This collaboration on LSD1 inhibition with Oryzon fulfils that mandate perfectly.” 

Carlos Buesa, CEO of Oryzon, added, “We are excited to work with Roche in developing ORY-1001 to make a significant difference for patients with AML and, hopefully, for patients in other disease areas as well. Roche is the global leader in oncology and haematology, with a tremendous expertise in clinical development; this was the primary reason to prioritize this alliance. The collaboration is recognition of our cutting-edge science and our experience in epigenetics, an approach that we believe holds great promise for many patient groups.” 

Under the terms of the agreement, Oryzon will receive an upfront payment and near-term milestones totalling $21 million, plus potential development, commercial and sales milestone payments across haematology, cancer and non-malignant indications that could exceed $500 million, together with tiered royalties on sales which range up to mid-double digits.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche Introduces Enhanced Whole Exome Sequencing Solution
The company has announced the launch of the SeqCap EZ MedExome Target Enrichment Kit1.
Wednesday, September 23, 2015
Roche Invests For The Future In Its Basel Site
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development.
Thursday, October 23, 2014
Roche, Garvan Institute Epigenomic Partnership
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.
Wednesday, August 20, 2014
Roche 454 Sequencing Systems Successfully Resolve Genetic Mutations in Blood Cancer Cases
International study presented at ASH Meeting demonstrates the potential of 454 Sequencing Systems to comprehensively characterize an individual’s blood cancer type to guide personalized therapy decisions.
Thursday, December 13, 2012
Roche and Agilent to Provide Continued Service and Support to Roche NimbleGen Microarray Customers
Transition of services beginning immediately.
Wednesday, November 07, 2012
Roche's Troponin T Nominated for International Inventor Award
European Patent Office nominates the team of Klaus Hallermayer from Roche Penzberg, jointly with Prof. Hugo Katus from the University of Heidelberg.
Monday, June 11, 2012
Roche and Life Technologies Corporation Sign New PCR IVD Licenses
Companies announced that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.
Thursday, February 23, 2012
Roche and Labcyte Integrate Echo and LightCycler Systems to Increase Performance of qPCR-based RNA/DNA Analyses
Companies cooperate around high-speed, miniaturized quantitative PCR (qPCR) to monitor the expression of tens to thousands of genes for therapeutic research.
Wednesday, December 07, 2011
Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
Roche NimbleGen, Inc. and BGI, a large genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology for Human Disease and Biomedical Research.
Tuesday, November 29, 2011
Complete Genome of Cynomolgus Monkey and Novel Gene Expression Microarray for Drug Safety Assessment
A team of researchers from Roche have generated the first draft genome sequence of the cynomolgus monkey and developed a novel microarray design for in depth expression profiling for use in preclinical drug safety research.
Thursday, September 22, 2011
Roche Buys Full Rights to Danoprevir from InterMune
Agreement reinforces Roche’s leadership in the fight against hepatitis C.
Wednesday, October 13, 2010
Roche and reMYND Enter Agreement to Develop First-in-Class Disease-Modifying Treatments for Parkinson’s and Alzheimer’s Disease
Novel therapies to target unmet needs in neurodegenerative disorders.
Tuesday, September 07, 2010
Macrogen, Inc. Certified as NimbleGen Array Service Provider for Korea
Macrogen has been certified to process customer samples for NimbleGen CGH/CNV services in their lab in Seoul.
Wednesday, July 14, 2010
Roche and Start Initiative for Early Discovery of New Diseases
The joint project is aimed to demonstrate the feasibility of developing a multidisciplinary surveillance, research and response system.
Wednesday, July 29, 2009
Roche Applied Science Opens Application Support Center in Shanghai
The new Application Support Center will apply broad range of technologies to a diverse range of life science research topics.
Friday, May 29, 2009
Scientific News
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
New Anti-Malarial Drug Screening Model
University of South Florida researchers demonstrate novel chemogenomic profiling to identify drug targets for the most lethal strain of malaria.
Coronavirus Breakthrough
Protein mutation affects spread and virulence of respiratory virus.
New, Better Test for Prostate Cancer
A study from Karolinska Institutet shows that a new test for prostate cancer is better at detecting aggressive cancer than PSA.
Circadian Clock Controls Insulin and Blood Sugar in Pancreas
Map of thousands of genes suggests new therapeutic targets for diabetes.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos